Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.
This article explains what thymalin is, where the name comes from, and what the published literature actually reports about it. Thymalin is not a single peptide with a sequence; it is an acid extract of calf thymus that contains many peptides. That fact shapes everything else: how it was studied, what a certificate can say about it, and why its evidence base reads very differently from that of a defined molecule such as thymosin alpha-1.
Thymalin is a polypeptide fraction from calf thymus, not a single sequence
Thymalin is the name given to a low-molecular-weight polypeptide fraction extracted from calf thymus by mild acid extraction, as described by Morozov and Khavinson in a 1997 review in the International Journal of Immunopharmacology. It has no single amino acid sequence, no single molecular weight, and no single PubChem entry. The same review reports that one component, the dipeptide L-Glu-L-Trp, was isolated from the thymalin fraction by reversed-phase HPLC and later synthesized under the name Thymogen. A 2023 International Journal of Molecular Sciences paper from the same group (Linkova and colleagues) describes two dipeptides, Lys-Glu (KE) and Glu-Trp (EW), as the "active substances" of the thymalin preparation, which tells you how the originating laboratory now thinks about the material: as a mixture whose activity it attributes to short fragments.
This places thymalin in the same category as the American thymic preparations of the 1970s. Goldstein and colleagues' 1977 Proceedings of the National Academy of Sciences paper on thymosin alpha-1 describes isolating that 28-residue peptide from "thymosin fraction 5", a calf thymus extract that was itself a mixture of dozens of polypeptides. Fraction 5 and thymalin are conceptually the same kind of material: a crude thymic fraction. The difference is that the American program went on to purify, sequence, and synthesize individual components, while the Soviet program kept the fraction itself as the product and registered it under the name Thymalin.
For a laboratory, the practical consequence is that "thymalin" on a label means "a thymus-derived peptide mixture prepared by a particular method", and the composition of that mixture is defined by the process, not by a structure.
The literature is Soviet and Russian in origin, and most of it is single-group
Nearly all primary thymalin papers come from one lineage of researchers in Leningrad and later St. Petersburg, centered on V. Kh. Khavinson and V. G. Morozov, with collaborators such as B. I. Kuznik in Chita. The earliest reports indexed in PubMed are a 1982 paper in Voenno-Meditsinskii Zhurnal (the Soviet military medical journal) titled "Experimental and clinical study of a new immunoregulator preparation thymalin" and a 1984 English-language summary by Safronov, Morozov, and Khavinson in Human Physiology. Most of the 1980s papers are in Russian, in journals such as Biulleten' Eksperimental'noi Biologii i Meditsiny, Farmakologiia i Toksikologiia, and Vestnik Khirurgii, and many have only a title or a two-sentence abstract in English.
Three features of this literature should be stated plainly. First, it is almost entirely single-group: the originating laboratory designed the studies, prepared the material, and reported the results. Second, independent replication outside Russia and its neighbors is close to absent. Third, the 1980s studies predate modern reporting standards, so group sizes, blinding, and statistical methods are often not recoverable from the abstract. None of this means the findings are wrong. It does mean they have not been tested the way the thymosin alpha-1 literature has been tested, and a careful reader keeps that difference in view.
A 2002 Advances in Gerontology paper by Khavinson and Morozov is the broadest claim in the set: it describes 266 older adults observed over six to eight years after receiving thymalin, a pineal extract called Epithalamin, or both, with lower rates of respiratory illness and lower mortality than a comparison group. The report is in Russian, the design was observational rather than randomized, and no independent group has repeated it.
What cell-culture studies measured
The in vitro thymalin papers report changes in surface markers, cytokine output, and signaling in cultured immune cells. Khavinson, Linkova, and colleagues' 2020 paper in the Bulletin of Experimental Biology and Medicine exposed cultured human hematopoietic stem cells to the thymalin fraction and measured marker expression by immunofluorescence. They reported that CD44 (a stem-cell marker) and CD117 (an intermediate-stage marker) fell by two to three times while CD28 (a marker of mature T lymphocytes) rose by 6.8 times, which they interpreted as a shift toward T-lymphocyte differentiation. The study had no sequence-defined control peptide, so it cannot say which component of the mixture produced the change.
Avolio, Martinotti, and colleagues' 2022 International Journal of Molecular Sciences paper compared five Khavinson materials, including the thymalin complex, in the human monocytic THP-1 cell line. All five increased tyrosine phosphorylation of mitogen-activated kinases, and all five reduced TNF and IL-6 expression in differentiated THP-1 cells after lipopolysaccharide stimulation. THP-1 cells exposed to the peptides also adhered less to lipopolysaccharide-activated HUVEC endothelial monolayers. The paper describes the materials by their trademarked names and lists Khavinson as a coauthor, so it is an extension of the originating group rather than an independent test.
Kuznetsova and colleagues' 2013 paper in Antibiotiki i Khimioterapiia is one of the few comparative studies: it placed thymalin alongside tinrostim, a peptide preparation from squid optic ganglia, in cultures of peripheral blood cells and reported that both raised TNF-alpha, IL-1, and IL-10 output. Describing the fraction as an immunomodulator in culture is consistent with these data; describing it as doing anything in a living person is not something the cell work can support.
Animal and tissue-localization studies
The animal literature is older and thinner. Grintsevich, Morozov, and Khavinson reported in a 1984 Radiobiologiia paper that irradiated guinea pigs given thymalin showed faster recovery of thymus structure and of several immune indices. Kuznik's group published a series of papers in the same period on thymectomized rats, measuring blood coagulation, fibrinolysis, and platelet aggregation after thymalin, which is where the idea that the fraction affects hemostasis originates. A 2000 Biogerontology paper by Anisimov, Khavinson, and Morozov studied not thymalin itself but its isolated dipeptide Glu-Trp in 76 female rats followed to natural death, reporting a longer maximum lifespan among the last-surviving ten percent and fewer spontaneous tumors. That study is sometimes cited as thymalin evidence; it is dipeptide evidence.
A separate line of work asks where thymalin-reactive material occurs in tissue. Khlystova, Kalinina, and Shmeleva reported in 2002, in the Bulletin of Experimental Biology and Medicine, that an antiserum raised against thymalin stained young cells of human epidermis and fetal thymic reticuloepithelium, and that the stained layer thinned and became discontinuous by about age 70. A 2003 paper from the same authors found similar staining in developing human fetal respiratory organs. These are descriptive immunohistochemical findings; because the antiserum was raised against a mixture, what it recognizes is a family of epitopes rather than one molecule.
| Model | Representative paper | What was measured |
|---|---|---|
| Human hematopoietic stem cells, culture | Khavinson et al., 2020, Bull Exp Biol Med | CD44, CD117, CD28 expression by immunofluorescence |
| THP-1 monocytes, culture | Avolio et al., 2022, Int J Mol Sci | MAPK phosphorylation; TNF and IL-6 after LPS; adhesion to HUVEC |
| Peripheral blood cells, culture | Kuznetsova et al., 2013, Antibiot Khimioter | TNF-alpha, IL-1, IL-10 output |
| Irradiated guinea pigs | Grintsevich et al., 1984, Radiobiologiia | Thymus histology and immune indices |
| Human tissue sections | Khlystova et al., 2002, Bull Exp Biol Med | Immunostaining of epidermis across ages |
How thymalin differs from thymosin alpha-1
Thymalin and thymosin alpha-1 are often listed together as "thymic peptides", but they are different kinds of object. Thymosin alpha-1 is a single 28-residue, N-acetylated, acidic peptide whose sequence has been known since Goldstein's 1977 paper, whose NMR structure was solved by Elizondo-Riojas and colleagues in 2011, and whose precursor, prothymosin alpha, and processing enzyme, legumain, were identified by Sarandeses and colleagues in a 2003 Journal of Biological Chemistry paper. It can be made by solid-phase synthesis to a defined purity and confirmed by mass spectrometry. Its literature includes independent groups on three continents, and a synthetic form is marketed abroad under the name thymalfasin. The thymosin alpha-1 overview covers that history, and the thymalin vs thymosin alpha-1 comparison puts the two side by side.
Thymalin cannot be made by synthesis at all, because there is no sequence to synthesize. A product called thymalin is either an extract prepared by the original acid-extraction method, or a synthetic stand-in built from one or more of the short peptides the originating group now names as its active components. Those are not the same material, and a vendor should say which one is in the vial.
| Thymalin | Thymosin alpha-1 | |
|---|---|---|
| Nature | Acid extract of calf thymus; a mixture | Single 28-residue peptide |
| Sequence | None (process-defined) | Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN |
| Identity test | Chromatographic fingerprint only | Mass spectrometry against a calculated mass |
| Origin of literature | Leningrad/St. Petersburg group, 1980s onward | Goldstein laboratory, 1977; many independent groups since |
| Approval status | Registered in Russia; not an approved drug in the US | Approved abroad as thymalfasin; not an approved drug in the US |
What a certificate can and cannot say about a fraction
A certificate of analysis for a single peptide reports an observed mass against a calculated one. For a mixture there is no calculated mass, so the identity line has to be something else: an HPLC profile compared with a reference lot, an amino acid composition, or a molecular-weight distribution by size-exclusion chromatography. A purity line in area percent is also hard to interpret, because every peak in a mixture is "product". The honest way to document a fraction is to state the method of preparation, show the chromatographic fingerprint, report net peptide content by amino acid analysis, and run the safety panel (endotoxin by LAL, sterility, heavy metals by ICP-MS) exactly as for any other lot. The article on certificate blind spots covers why those lines matter more here than the purity figure.
If a vendor's thymalin is actually a synthetic dipeptide or a defined blend, the certificate should say so and should then look like a normal peptide COA, with an expected mass for each component. US Prime Peptides posts the lot-matched certificate on each product page, including Thymalin 10 mg and Thymalin 20 mg, so a buyer can read exactly which kind of material the document describes before ordering.
Frequently Asked Questions
Is thymalin the same as thymosin alpha-1?
No. Thymosin alpha-1 is a single 28-residue peptide with a known sequence, first described by Goldstein and colleagues in 1977. Thymalin is an acid extract of calf thymus containing many peptides, described by Morozov and Khavinson. One is a molecule; the other is a process-defined mixture.
What is the amino acid sequence of thymalin?
It does not have one. Thymalin is a polypeptide fraction, so its composition is set by the extraction method rather than by a structure. The originating laboratory has since named two dipeptides, Lys-Glu and Glu-Trp, as the components it considers active, and Glu-Trp was separately synthesized as Thymogen.
Has thymalin research been replicated outside Russia?
Very little of it. Nearly every primary paper comes from the Khavinson and Morozov lineage in St. Petersburg or from collaborators in Russia and Ukraine, and many are published in Russian. The 2022 THP-1 cell study in an international journal listed Khavinson as a coauthor. Independent replication of the main claims has not been published.
Is thymalin an approved drug?
Thymalin is registered as a drug in Russia. It is not an approved drug in the United States, and a research-grade vial labeled thymalin is supplied for in vitro laboratory use only. The FDA status reference table lists it alongside other research peptides.
Citations
- Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A. 1977;74:725-729. PMID 265536
- Morozov VG, Khavinson VK. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. 1997;19:501-505. PMID 9637345
- Khavinson VKh, Morozov VG. [Experimental and clinical study of a new immunoregulator preparation thymalin]. Voen Med Zh. 1982;(5):37-39. PMID 7048731
- Safronov BN, Morozov VG, Khavinson VKh. Experimental and clinical study of the thymus polypeptide factor thymalin. Hum Physiol. 1984;10:97-101. PMID 6336212
- Grintsevich II, Morozov VG, Khavinson VKh. [Effect of thymalin on the thymus and immunologic indices of irradiated animals]. Radiobiologiia. 1984;24:537-540. PMID 6548035
- Anisimov VN, Khavinson VK, Morozov VG. Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology. 2000;1:55-59. PMID 11707921
- Khavinson VKh, Morozov VG. [Geroprotective effect of thymalin and epithalamin]. Adv Gerontol. 2002;10:74-84. PMID 12577695
- Khlystova ZS, Kalinina II, Shmeleva SP. Age-related changes of thymalin content in human epidermis. Bull Exp Biol Med. 2002;133:620-622. PMID 12447484
- Kuznetsova TA, Besednova NN, Zaporozhets TS, et al. [Comparative study of immunomodulatory activity of peptides, tinrostim and thymalin]. Antibiot Khimioter. 2013;58:8-12. PMID 24734422
- Khavinson VK, Linkova NS, Kvetnoy IM, et al. Thymalin: activation of differentiation of human hematopoietic stem cells. Bull Exp Biol Med. 2020;170:118-122. PMID 33237528
- Avolio F, Martinotti S, Khavinson VK, et al. Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. Int J Mol Sci. 2022;23:3607. PMID 35408963
- Linkova N, Khavinson V, Diatlova A, et al. The influence of KE and EW dipeptides in the composition of the thymalin drug on gene expression and protein synthesis involved in the pathogenesis of COVID-19. Int J Mol Sci. 2023;24:13377. PMID 37686182
- Sarandeses CS, Covelo G, Díaz-Jullien C, Freire M. Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase. J Biol Chem. 2003;278:13286-13293. PMID 12554742
- Elizondo-Riojas MA, Chamow SM, Tuthill CW, et al. NMR structure of human thymosin alpha-1. Biochem Biophys Res Commun. 2011;416:356-361. PMID 22115779
This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.
Related research
Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.
